Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials

References

• Vazquez-Mellado J, Jimenez-Vaca AL, Cuevas-Covarrubias S, Alvarado-Romano V, Pozo-Molina G, Burgos-Vargas R. Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout. Rheumatology (Oxford). 2006;46(2):215–9.
   PubMed Web of Science ®Google Scholar
• Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs. 2011;71(11):1413–39.
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Andrews LM, Yadao AM, Kahler KH. The effect of gout on health-related quality of life, work productivity, resource use and clinical outcomes among patients with hypertension. Expert Rev Pharmacoecon Outcomes Res. 2012;12(6):821–9.
   PubMed Web of Science ®Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431–46.
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–24.
   PubMed Web of Science ®Google Scholar
• Yamanaka H. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018–29.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Metabolism TG. Essence of the revised guideline for the management of hyperuricemia and gout. Japan Med Assoc J. 2012;55(4):324–9.
   PubMedGoogle Scholar
• Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol. 2014;10(5):271–83.
   PubMed Web of Science ®Google Scholar
• Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6-month phase 3 clinical trial and extension study. Rheumatology (Oxford). 2017;56(12):2170–8.
   PubMed Web of Science ®Google Scholar
• Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017;76(5):811–20.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: Findings of a phase III clinical trial. Arthritis Rheumatol. 2017;69(9):1903–13.
   PubMed Web of Science ®Google Scholar
• Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 2017;69(1):203–12.
   PubMed Web of Science ®Google Scholar
• Pascual E, Andres M, Vela P. Gout treatment: should we aim for rapid crystal dissolution?. Ann Rheum Dis. 2013;72(5):635–7.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford). 2009;48 Suppl 2 (Suppl 2):ii9–ii14.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47(4):356–60.
   PubMed Web of Science ®Google Scholar
• Shiozawa A, Buysman EK, Korrer S. Serum uric acid levels and the risk of flares among gout patients in a US managed care setting. Curr Med Res Opin. 2017;33(1):117–24.
   PubMed Web of Science ®Google Scholar
• Terkeltaub R, Perez-Ruiz F, Kopicko J, Fung M, Bhakta N, Adler S, et al. The safety and efficacy of lower serum urate levels: a pooled analysis of gout subjects receiving lesinurad and xanthine oxidase inhibitors. Arthritis Rheumatol 2015;67:Abstract 2354. http://acrabstracts.org/abstract/the-safety-and-efficacy-of-lower-serum-urate-levels-a-pooled-analysis-of-gout-subjects-receiving-lesinurad-and-xanthine-oxidase-inhibitors/.
   PubMed Web of Science ®Google Scholar
• Tan PK, Liu S, Gunic E, Miner JN. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout. Sci Rep. 2017;7(1):665.
   PubMed Web of Science ®Google Scholar
• Shen Z, Gillen M, Miner JN, Bucci G, Wilson DM, Hall JW. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects. Drug Des Dev Ther. 2017;11:2077–86.
   PubMed Web of Science ®Google Scholar
• Hall J, Gillen M, Liu S, Miner JN, Valdez S, Shen Z, Lee C. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects. Drug Des Dev Ther. 2018;12:1799–807.
   PubMed Web of Science ®Google Scholar
• Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895–900.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Hernandez-Baldizon S, Herrero-Beites AM, Gonzalez-Gay MA. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout. Arthritis Care Res (Hoboken). 2010;62(9):1299–305.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Liu S, Shen Z, Yan X, Yamamoto A, Gillen M, et al. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology (Oxford). 2018;57(9):1602–10. doi: 10.1093/rheumatology/key100.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Winkle P, Hall J, Valdez S, Liu S, Yan X, et al. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study. RMD Open. 2018;4(1):e000647. doi: 10.1136/rmdopen-2018-000647. eCollection 2018.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Winkle P, Miner JN, Yan X, Hicks L, Valdez S, Hernandez-Illas M et al., Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open. 2018;4(1):e000584. doi: 10.1136/rmdopen-2017-000584. eCollection 2018.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016;75(6):1074–80.
   PubMed Web of Science ®Google Scholar
• Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643–65.
   PubMed Web of Science ®Google Scholar